6 Papers
45 Citations
John Martin is an academic researcher from University of Medicine and Dentistry of New Jersey. The author has contributed to research in topics: 12-O-Tetradecanoylphorbol-13-acetate & Blood lipids. The author has an hindex of 5, co-authored 6 publications.
Chat about Author
Papers
Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records.
Patrick J. Boyle,Allen B. King,Leann Olansky,Albert Marchetti,Helen Lau,Raf Magar,John Martin +6 more
TL;DR: Treatment with piog litazone was associated with greater beneficial effects on blood lipid levels than treatment with rosiglitazone, whereas glycemic control was equivalent between the 2 treatments.
170
A phase I clinical trial of 12- O -tetradecanoylphorbol-13-acetate for patients with relapsed/refractory malignancies
Dale G. Schaar,Lauri Goodell,J. Aisner,Xiao Xing Cui,Zheng Tao Han,Richard L. Chang,John Martin,Stephanie Grospe,Liesel Dudek,Joan Riley,Jacqueline Manago,Yong Lin,Eric H. Rubin,Allan H. Conney,Roger K. Strair +14 more
TL;DR: 0.125 mg/m2 is established as the maximally tolerated dose when TPA is administered on this schedule, and a phase I dose escalation trial of TPA was undertaken for patients with relapsed or refractory malignancies.
52
Longitudinal assessment of the dose consistency of botulinum toxin type A (BOTOX®) for cervical dystonia
TL;DR: It is indicated that doses of and intervals between BoNT/A treatments for cervical dystonia were consistent throughout 2 years of observation.
26
Treatments for mild-to-moderate recalcitrant plaque psoriasis: expected clinical and economic outcomes for first-line and second-line care.
Albert Marchetti,Steven R. Feldman,Alexandra B. Kimball,R. Rox Anderson,Laurence H Miller,John Martin,Peter An +6 more
TL;DR: The addition of the 308-nm excimer laser to the rotational mix of treatments commonly utilized as second-line therapies for mild-to-moderate plaque psoriasis is expected to add incremental clinical benefit for patients without incremental cost for payers.
23
12-O-Tetradecanoylphorbol-13-acetate (TPA)-induced dual-specificity phosphatase expression and AML cell survival
Dale G. Schaar,Hao Liu,Shashi Sharma,Yi Ting,John Martin,Curtis Krier,Marie Ciardella,Mona Osman,Lauri Goodell,Daniel A. Notterman,Roger K. Strair +10 more
TL;DR: A subset of primary AML samples that undergoes apoptosis after exposure to TPA is identified and it is demonstrated that TPA-induced cytotoxicity is associated with modulation of the ERK signaling pathway.
16